Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.53 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926533 | 0.85 | SMN1; SMN2 (0.66) | NPC1TDP1GAANAMPTANO1 | |
| SCHEMBL9926520 | 0.84 | MEN1 (0.55) | NPC1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL9926569 | 0.79 | PYGL (0.52) | NAMPTLMNAERCC1ERCC4HTT | |
| SCHEMBL9926519 | 0.77 | POLB (0.58) | NPC1ANO1MAPTKMT2AMEN1 | |
| SCHEMBL22307433 | 0.76 | GAA (0.66) | GAANAMPTLMNAMAPTKMT2A | |
| SCHEMBL30172092 | 0.76 | LMNA (0.86) | GAALMNAMAPTKMT2AERCC1 | |
| SCHEMBL28497414 | 0.76 | LMNA (0.86) | GAALMNAMAPTKMT2AERCC1 | |
| SCHEMBL9926561 | 0.75 | KMT2A (0.65) | NPC1ANO1KMT2AMEN1ERCC1 | |
| SCHEMBL31207025 | 0.75 | GAA (0.57) | GAALMNAMAPTKMT2AMEN1 | |
| SCHEMBL31321081 | 0.74 | MAPT (0.69) | GAALMNAMAPTKMT2ANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | NPC1 3324/4885TDP1 389/4885GAA 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.